Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2021-02-03 Declaration of Voting R…
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It provides a table showing the total number of shares and theoretical voting rights as of January 31, 2021. This content directly relates to changes in the company's capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA). Although it is a direct publication of data, it is not merely an announcement of a report (RPA) but the report itself detailing the capital structure update. It is more specific than the general 'Regulatory Filings' (RNS).
2021-02-03 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "BIOCORP : Agenda financier 2021" and presents a schedule of future financial events, including the announcement of annual results, the General Meeting (Assemblée Générale), and half-year results. It is not the actual report (like 10-K or IR) but rather an announcement detailing *when* future reports and meetings will occur. Since it is an announcement about the timing of future corporate events, specifically the Annual General Meeting (AGM) date is listed, it aligns best with an announcement related to corporate governance or future reporting schedules. Given the options, this document primarily serves to inform stakeholders about the schedule of key corporate events, including the AGM date. While it could be seen as a general regulatory filing (RNS), the specific mention of the 'Assemblée Générale' date makes it highly relevant to AGM planning. However, the core content is a forward-looking schedule of announcements, not the AGM material itself. Since it announces the date of the AGM, and also the dates for results announcements, it functions as a general corporate update regarding future reporting. Given the short length (1930 chars) and the nature of providing a schedule for future events, it is most accurately classified as a Report Publication Announcement (RPA) if it were announcing the release of a specific report, but here it announces the schedule of multiple events. Since it explicitly lists the date for the 'Assemblée Générale', and the document is short and serves as a notice, it is best classified as a general regulatory announcement (RNS) or potentially related to AGM planning. Given the options, and that it is a forward-looking schedule rather than the actual report or a specific AGM presentation, RNS (Regulatory Filings) is the most appropriate fallback for a general corporate calendar announcement that doesn't fit the specific report types.
2021-01-06 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is titled 'BIOCORP: 2021 financial calendar' and explicitly lists the dates for future announcements, including '2020 full-year results', 'Annual shareholders meeting', and '2020 first-half results'. This content is a schedule or calendar detailing when future reports and meetings will occur, not the reports themselves. Since it is an announcement about the timing of future corporate events and reports, it best fits the category for announcing the publication of reports, which is Report Publication Announcement (RPA). It is too specific for the general Regulatory Filings (RNS) fallback.
2021-01-06 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It provides a specific date (December 31, 2020) for the total number of shares and voting rights. This content directly relates to changes in the company's capital structure or share count, which aligns with the definition of 'Share Issue/Capital Change' (SHA). Although it is a publication, the core information is the capital structure data itself, not just an announcement that a report is available (which would suggest RPA or RNS). Since it details the exact number of shares and voting rights, SHA is the most precise fit.
2021-01-05 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "Bilan annuel du contrat de liquidité BIOCORP confié à la société de Bourse Gilbert Dupont" (Annual balance of the liquidity contract entrusted to the brokerage firm Gilbert Dupont). It details the status of a liquidity contract (share buyback/stabilization agreement) as of December 31, 2020, including the number of shares and cash held, and transaction volumes for Q2 2020. This type of filing, which reports on the company's own shares being managed or transacted under a specific agreement (often related to market making or stabilization), directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), a full annual report (10-K), or a management report (MDA).
2021-01-05 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It provides a table showing the total number of shares and theoretical voting rights as of November 30, 2020. This content directly relates to the company's share structure and voting rights, which falls under the category of Share Issue/Capital Change (SHA) or potentially a general regulatory announcement. Since it explicitly details the total number of shares and voting rights, SHA is the most precise fit, as it concerns the capital structure. It is not a dividend notice (DIV), director dealing (DIRS), or a major shareholding notification (MRQ) which usually concerns changes by external parties crossing thresholds. It is a formal announcement regarding the capital structure.
2020-12-04 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.